Investor Presentation Full Year 2021
56
Investor presentation Full year 2021
SaxendaⓇ addresses a global unmet need for medical weight
management
Global obesity prevalence
SaxendaⓇ launched countries
Global reimbursement status
Novo NordiskⓇ
80% access in commercial channel, but due to
employer opt-in, effective access is around 20%
Reimbursement is predominantly out-of-pocket
NICE has recommended SaxendaⓇ for use by
NHS in select patient populations
~60% coverage by private insurance, 20% of
which includes restricted/unrestricted coverage
<10% <10-19.9% <20-29.9% >30%
SaxendaⓇ now launched in 65 countries
+
SaxendaⓇ reimbursed on April 2020 in selected
patient groups
Note: Wegovy has been launched in the US (June 2021).
NAO: North America Operations; IO: International Operations; EMEA: Europe, Middle East and Africa; ROW: Rest of World; NICE: National Institute for Health and Care Excellence; NHS: National Health Service
Source: World Health Organisation (WHO) - Global Health Observatory, 2016. Obesity defined as BMI > 30 (BMI: Body Mass Index)View entire presentation